AXSM · Axsome Therapeutics, Inc. · Webcasts, Transcripts & Audio
$141.69
-2.68 (-1.86%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$7.45B
Shares
52.60M
Volume · Nov 13
973.14K
Avg daily vol (3M)
847.81K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Axsome Therapeutics, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Axsome Therapeutics, Inc. (AXSM), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-11-16
Axsome Therapeutics, Inc. (AXSM) November 16, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-09
Axsome Therapeutics, Inc. (AXSM) November 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-11-02
Axsome Therapeutics, Inc. (AXSM) Q3 2026 Earnings Call Transcript
Confident tone
Aveli demand in Alzheimer's disease agitation and MDD
Commercial portfolio expansion beyond Aveli
AXS-12 regulatory review and cataplexy opportunity
Revenue
$259.69M
▲ 51.9% YoY Diluted EPS
$-0.25
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-16
Axsome Therapeutics, Inc. (AXSM) September 16, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-14
Axsome Therapeutics, Inc. (AXSM) September 14, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-09
Axsome Therapeutics, Inc. (AXSM) September 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-10
Axsome Therapeutics, Inc. (AXSM) Q2 2026 Earnings Call Transcript
Confident tone
Alzheimer's disease agitation launch
Sales force expansion
Gross-to-net and financials
Revenue
$218.38M
▲ 45.5% YoY Diluted EPS
$-0.99
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-08
Axsome Therapeutics, Inc. (AXSM) June 8, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-08
Axsome Therapeutics, Inc. (AXSM) June 8, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-04
Axsome Therapeutics, Inc. (AXSM) June 4, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-03
Axsome Therapeutics, Inc. (AXSM) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-19
Axsome Therapeutics, Inc. (AXSM) May 19, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-12
Axsome Therapeutics, Inc. (AXSM) May 12, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-12
Axsome Therapeutics, Inc. (AXSM) May 12, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-04
Axsome Therapeutics, Inc. (AXSM) Q1 2026 Earnings Call Transcript
Confident tone
Pipeline advancement and NDA submissions
Avelity FDA approval in Alzheimer's disease agitation (ADA)
Sunosi and Symbravo commercial performance
Revenue
$191.20M
▲ 57.4% YoY Diluted EPS
$-1.26
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-23
Axsome Therapeutics, Inc. (AXSM) Q4 2025 Earnings Call Transcript
Confident tone
Auvelity commercial growth
Cymbravo launch
Solriamfetol label expansion pipeline
Revenue
$196.00M*
▲ 65% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-03
Axsome Therapeutics, Inc. (AXSM) Q3 2025 Earnings Call Transcript
Confident tone
AXS-12 narcolepsy NDA
AUVELITY commercial performance
AXS-05 Alzheimer's disease agitation
Revenue
$170.99M
▲ 63.2% YoY Diluted EPS
$-0.94
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-04
Axsome Therapeutics, Inc. (AXSM) Q2 2025 Earnings Call Transcript
Confident tone
Commercial growth / Auvelity and Sunosi
SYMBRAVO launch
Solriamfetol expansion indications
Revenue
$150.04M
▲ 72.1% YoY Diluted EPS
$-0.97
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-05
Axsome Therapeutics, Inc. (AXSM) Q1 2025 Earnings Call Transcript
Confident tone
Revenue growth & commercial performance
Solriamfetol lifecycle expansion (ADHD, MDD, BED, SWD)
Symbravo launch & EMERGE data
Revenue
$121.46M
▲ 62% YoY Diluted EPS
$-1.22
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-18
Axsome Therapeutics, Inc. (AXSM) Q4 2024 Earnings Call Transcript
Confident tone
Late-stage pipeline and NDAs
Auvelity commercial growth
Solriamfetol label expansion
Revenue
$118.77M*
▲ 66% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Axsome Therapeutics, Inc. (AXSM) Q3 2024 Earnings Call Transcript
Confident tone
Auvelity commercial momentum
Solriamfetol (AXS-12 / Sunosi) life-cycle expansion
AXS-05 Alzheimer's disease agitation Phase 3 readouts
Revenue
$104.76M
▲ 81.3% YoY Diluted EPS
$-1.34
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-05
Axsome Therapeutics, Inc. (AXSM) Q2 2024 Earnings Call Transcript
Confident tone
Auvelity commercial momentum
Solriamfetol pipeline expansion
Sunosi performance
Revenue
$87.17M
▲ 86.7% YoY Diluted EPS
$-1.67
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-06
Axsome Therapeutics, Inc. (AXSM) Q1 2024 Earnings Call Transcript
Confident tone
Alzheimer's disease agitation program
Auvelity commercial performance
Solriamfetol pipeline expansion
Revenue
$75.00M
▼ 20.7% YoY Diluted EPS
$-1.44
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-20
Axsome Therapeutics, Inc. (AXSM) Q4 2023 Earnings Call Transcript
Confident tone
Sunosi revenue and out-licensing
AXS-05 in Alzheimer's disease agitation (ADVANCE-2)
AXS-12 in narcolepsy (SYMPHONY trial)
Revenue
$71.53M*
Rev · 7q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-06
Axsome Therapeutics, Inc. (AXSM) Q3 2023 Earnings Call Transcript
Revenue
$57.79M
▲ 243.1% YoY Diluted EPS
$-1.32
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-07
Axsome Therapeutics, Inc. (AXSM) Q2 2023 Earnings Call Transcript
Revenue
$46.70M
▲ 429.5% YoY Diluted EPS
$-1.54
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-08
Axsome Therapeutics, Inc. (AXSM) Q1 2023 Earnings Call Transcript
Revenue
$94.58M
Diluted EPS
$-0.26
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-27
Axsome Therapeutics, Inc. (AXSM) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-07
Axsome Therapeutics, Inc. (AXSM) Q3 2022 Earnings Call Transcript
Revenue
$16.85M
Diluted EPS
$-1.07
Gross margin
88.7%
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-23
Axsome Therapeutics, Inc. (AXSM) Q2 2022 Earnings Call Transcript
Revenue
$8.82M
Diluted EPS
$-1.06
Gross margin
88.7%
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-02
Axsome Therapeutics, Inc. (AXSM) Q1 2022 Earnings Call Transcript
Diluted EPS
$-1.06
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-01
Axsome Therapeutics, Inc. (AXSM) Q4 2021 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-08
Axsome Therapeutics, Inc. (AXSM) Q3 2021 Earnings Call Transcript
Revenue
$0
Diluted EPS
$-0.93
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-09
Axsome Therapeutics, Inc. (AXSM) Q2 2021 Earnings Call Transcript
Revenue
$0
Diluted EPS
$-0.86
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-10
Axsome Therapeutics, Inc. (AXSM) Q1 2021 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-01
Axsome Therapeutics, Inc. (AXSM) Q4 2020 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Axsome Therapeutics, Inc. (AXSM) Q3 2020 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-10
Axsome Therapeutics, Inc. (AXSM) Q2 2020 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-08
Axsome Therapeutics, Inc. (AXSM) Q1 2020 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-12
Axsome Therapeutics, Inc. (AXSM) Q4 2019 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Showing 1–40 of 40 webcasts
Key facts
CIK
1579428
CUSIP
05464T104
13F (30d)
362 filings
326 filers
Visit website
Investor relations